Status:

COMPLETED

Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies

Lead Sponsor:

University of Michigan

Collaborating Sponsors:

National Institutes of Health (NIH)

National Cancer Institute (NCI)

Conditions:

Breast Cancers

Eligibility:

FEMALE

25+ years

Phase:

NA

Brief Summary

The purpose of this study is to determine how well changes can be determined in malignant masses from ultrasound scans.

Detailed Description

To evaluate the proportions of correct diagnosis of response to breast Cancer therapies for localized breast cancer by ultrasound. To develop a model based on patient characteristics, physical exam, a...

Eligibility Criteria

Inclusion

  • Newly diagnosed breast cancer prior to receiving breast cancer therapy.
  • Diagnosis of breast cancer must be confirmed by fine needle aspiration or core biopsy.

Exclusion

  • Poorly controlled diabetes.
  • Contralateral mastectomy prior to neoadjuvant chemotherapy.
  • Not a surgical candidate.
  • No previous axillary lymph node dissection.

Key Trial Info

Start Date :

March 1 2000

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2014

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT00721903

Start Date

March 1 2000

End Date

September 1 2014

Last Update

May 5 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Michigan Hospital

Ann Arbor, Michigan, United States, 48109

Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies | DecenTrialz